Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?

by Gijs F. N. Berkelmans, Jacoba P. Greving, Yolanda van der Graaf, Frank L. J. Visseren, Jannick A. N. Dorresteijn
Published 2020-04-01

Identifying treatment response to antihypertensives in patients with obesity-related hypertension

by Ilse M. Schrover, Jannick A. N. Dorresteijn, Jodine E. Smits, A. H. Jan Danser, Frank L. J. Visseren, Wilko Spiering
Published 2017-10-01

Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-expectancy: does it improve decisional conflict? Three-armed, blinded, randomised controlled...

by Yvo M Smulders, Guy E H M Rutten, Frank L J Visseren, Yolanda van der Graaf, Olga C Damman, Nicole E M Jaspers, Jannick A N Dorresteijn, Corline Brouwers
Published 2021-07-01

Routinely measured hematological parameters and prediction of recurrent vascular events in patients with clinically manifest vascular disease.

by Daniel Kofink, Steven A Muller, Riyaz S Patel, Jannick A N Dorresteijn, Gijs F N Berkelmans, Mark C H de Groot, Wouter W van Solinge, Saskia Haitjema, Tim Leiner, Frank L J Visseren, Imo E Hoefer, Folkert W Asselbergs, SMART Study Group
Published 2018-01-01